ArticleAdvanced healthcare materials2026
Hydrocolloid-Based Multiwavelength Stretchable QD-OLED Patch for Simultaneous Neonatal Jaundice and Dermatitis Treatment with Biosignal Monitoring.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Conventional light-emitting-diode-based light sources suffer from rigidity, localized heating, and poor adaptability to skin deformation, limiting their use in skin-attached medical devices. To address these challenges, a quantum dot organic light-emitting diode (QD-OLED) architecture utilizing a blue OLED with QD for wavelength conversion is developed, achieving dual-wavelength emission (470 and 630 nm) in a simplified structure. The use of hydrocolloid as a substrate ensures skin adhesion, moisture retention, and attachability. The device exhibits high mechanical resilience with 190% stretchability and stable optical performance under deformation for over 80 h at low temperatures (<39 °C). By combining photomedicine functionality with flexibility, the platform demonstrates 26% bilirubin degradation under blue light and 46% human skin keratinocyte (HaCaT) cell proliferation under red light. Furthermore, the integration of organic photodiodes enables real-time biosignal detection, such as photoplethysmography, expanding the platform's potential in personalized healthcare systems. This study highlights the convergence of emerging electronic materials, QD-OLED, stretchable substrates, and organic sensors as a viable route for next-generation medical devices that integrate treatment, sensing, and skin-conformal mechanics in a single patch-type system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.